88 results
8-K
EX-99.1
IMNM
Immunome, Inc.
12 Aug 24
Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update
4:05pm
cash runway is expected to extend into 2026.
Research and development expenses for the quarter ended June 30, 2024 were $29.1 million, including … stock-based compensation costs of $1.0 million.
In-process research and development expenses for the quarter ended June 30th, 2024 were $6.3 million
424B5
IMNM
Immunome, Inc.
14 May 24
Prospectus supplement for primary offering
8:48am
intend to use the net proceeds, if any, of this offering, for general corporate purposes, including research and development and working capital. See … , business strategy, research and development costs, the anticipated timing, costs and conduct of our planned clinical trials for our product candidates
8-K
EX-99.1
ml5se
14 May 24
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
8:02am
8-K
EX-99.1
w18zlb4h1xtfl
28 Mar 24
Immunome Reports Full-Year 2023 Financial Results and Provides Update on Recently Acquired Assets
4:04pm
8-K
znms3
26 Mar 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
8:05am
8-K
EX-10.1
vhp kh2qmnkf7
26 Mar 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
8:05am
8-K
EX-1.1
ivsy qzud02nl7
14 Feb 24
Other Events
4:11pm
424B5
3lbl8c0 22tf
14 Feb 24
Prospectus supplement for primary offering
4:09pm
424B5
1gpk7c991 fr5y3afrbf
13 Feb 24
Prospectus supplement for primary offering
4:36pm
8-K
hybgw0ygs83szhf9s
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-99.1
1i1ict rx
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-99.2
p2ktxy2758 rsilroyn0
13 Feb 24
Results of Operations and Financial Condition
4:10pm
S-3ASR
999kw6wdpcts4f w4q
13 Feb 24
Automatic shelf registration
4:04pm
8-K
EX-2.1
gag990k4
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
8-K/A
EX-99.2
zm0w2onhi243gtlkhv
22 Nov 23
Report of Independent Auditors
4:02pm